VENUS MEDTECH-B (02500) surged more than 7%, reaching HK$2.44 by the time of writing, with a trading volume of HK$4.54 million. The rise follows the company's announcement on November 19 of mid-term clinical results for its innovative transcatheter tricuspid valve replacement system, Cardiovalve, from the TARGET study.

The TARGET study is a prospective, multicenter, single-arm clinical trial involving 125 patients with an average age of 77 across 25 centers in Germany, Spain, Italy, Canada, and the UK. Results showed an average procedure time of 58±29 minutes, an intraoperative success rate of 88%, and an implantation success rate of 95%.

At the six-month follow-up, 100% of patients exhibited no moderate or greater regurgitation, with 88% showing improved cardiac function to Class I/II, increasing to 90% at 12 months. Quality-of-life questionnaires indicated an average improvement of 20 points, while the six-minute walking distance increased by 44 meters and 32 meters, respectively.

Safety data revealed an all-cause mortality rate of 6.4% (8/125), a heart failure rehospitalization rate of 1.6%, and low incidences of pericardial tamponade, disabling stroke, and acute kidney injury requiring renal replacement therapy.

VENUS MEDTECH-B highlighted that the mid-term clinical data for the Cardiovalve system, presented at the PCR London Valves 2025 conference, demonstrated its outstanding efficacy in treating severe tricuspid regurgitation, earning high recognition from international clinical experts. The company remains committed to advancing global clinical registration for innovative products, including the Cardiovalve system.